Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard(University of North Carolina at Chapel Hill), Daniel Ambrosio, John Vissing(University of Copenhagen), David Feder, Kimiaki Utsugisawa(National Hospital Organization Hanamaki Hospital), Mahi Jasinarachchi, Alzira Alves de Siqueira Carvalho(Centro Universitário Fundação Santo André), Philip Van Damme(Universitair Ziekenhuis Leuven), Guy Van den Abeele, Kathy de Koning, Mariela Bettini, Fanny O’Brien(Alexion Pharmaceuticals (United States)), Délphine Mahieu, Michael Benatar(University of Miami), Juliet Saba, Renato Mantegazza(Italian Association for Cancer Research), Saiju Jacob(Institute of Immunology), Ted M. Burns(University of Virginia), Miguel Wilken, Beverly Fyfe, Richard J. Barohn(University of Missouri), Isabel Illa(Hospital de Sant Pau), Gonzalo Vidal, Carolina Ortea, Heidi Boterhoven, Rudy Mercelis, Julia Wanschitz(Innsbruck Medical University), Charlotte Smetcoren, Sarah Verjans, Petra Tilkin, Richard J. Nowak(Yale University), Ann D’Hondt(KU Leuven), Olivier Stevens, Linda Wagemaekers, Igor Dias Brockhausen, Alejandra Dalila Garcia, Hiroyuki Murai(Kyushu University), Marcelo Rugiero, Jan De Bleecker(Ghent University Hospital), Rosa Hasan, Katrien De Mey, Claudio Mazia, Natasha Willlems, Jingjing Wang(Beijing Xuanwu Traditional Chinese Medicine Hospital), L. Jackson Roberts(The University of Melbourne), John T. Kissel(The Ohio State University), Wolfgang N. Löscher(Innsbruck Medical University), Phillipa J. Lamont(Royal Perth Hospital), Srikanth Muppidi(Stanford Health Care)
The Lancet Neurology
October 23, 2017
Cited by 820


Related Papers